Clinical effect analysis of Ambroxol combined with new nasal continuous positive airway pressure treatment for 55 patients with neonatal hyaline membrane disease

Objective To explore the therapeutic effect and complications of ambroxol combined with new nasal continuous positive airway pressure(NCPAP) treatment of neonatal pulmonary hyaline membrane disease(NHMD). Methods 55 NHMD patients were selected from Putuo Hospital of Zhoushan City, from January 2008 to December 2013, all patients were divided into the control group and the observation group. 27 cases in control group were treated with NCPAP therapy, 28 cases in observation group were treated with Ambroxol treatment on the basis of the control group. Results ①The total effective rate of the observation group was 89.29%(25/28), it was higher than that of the control group [66.67%(20/27)], the difference was statistically significant(P 0.05). The invalid rate of the observation group was 10.71%(3/28), it was lower than that of the control group [33.33%(9/27)], the difference was statistically significant(P 0.05). ②The PaO2ventilation for 24, 48 h in observation group were(62.69±2.51),(79.32±2.85) mm Hg respectively, they were all higher than those in control group [(51.37±2.64),(70.58±2.76) mmHg], the differences were statistically significant(P 0.05). The PaCO2ventilation for 24, 48 h in observation group were(53.38±2.06),(48.53±1.94) mm Hg respectively, they were all lower than those in control group [(58.26±2.14),(53.02±2.12) mm Hg], the differences were statistically significant(P 0.05). The PaO2/FiO2ventilation for 24, 48 h in observation group were(18.58±1.62),(22.64±1.15) respectively, they were all higher than those in control group [(58.26±2.14),(19.83±1.10)], the differences were statistically significant(P 0.05). ③The complication occurrence rate of the observation group was 17.86%(5/ 28), it was lower than that of the control group [48.15%(13/27)], the difference was statistically significant(P 0.05). The hospitalization time of the observation group was(25.34 ±1.92) d, it was lower than that of the control group [(30.82±2.21)d], the difference was statistically significant(P 0.05). Conclusion Ambroxol combined with NCPAP for the treatment of NHMD in children has good effect, which can reduce the complications and improve lung function.